| Serial Number | 87724721 |
| Word Mark | TRANSBIOTICS |
| Filing Date | Monday, December 18, 2017 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, November 25, 2019 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 28, 2018 |
| Goods and Services | Cultures of microorganisms other than for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Cultures of microorganisms other than for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in plants, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Cultures of microorganisms other than for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in plants, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions use as ingredients for food and beverages, namely, genetically engineered probiotic bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions for use as ingredients for food and beverages, namely, genetically modified probiotic bacteria configured to produce bioavailable nutritional compounds; Cultures of microorganisms for medical or agricultural use, namely, genetically modified endophytic bacteria for use in therapeutic treatment of pathogens in plants |
| Goods and Services | Cultures of microorganisms for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Biological preparations for the treatment of infectious diseases in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target animal pathogen genes; Biological preparations for the treatment of infectious diseases in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target plant pathogen genes; Biological preparations for the treatment of viral infections in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target viral pathogen genes; Biological preparations for the treatment of bacterial infections in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target bacterial pathogen genes; Biological preparations for the treatment of fungal diseases, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target fungal pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in animals, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Probiotic preparations for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in animals, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified enteric bacteria for use in therapeutic treatment of pathogens in animals; Medical, biological and pharmaceutical preparations for the prevention and treatment of infectious diseases in plants and animals; biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals; Cultures of microorganisms for medical or veterinary use, namely, biological RNA-based therapeutic agents that inhibit the expression of target genes in plant pests and herbivores |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 4, 2018 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, July 2, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | PEBBLE LABS INC. |
| Party Type | 21 - New Owner After Publication |
| Legal Entity Type | 03 - Corporation |
| Address | SANTA FE, NM 87501 |
| Party Name | Pebble Labs, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Los Alamos, NM 87544 |
| Party Name | Pebble Labs, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Los Alamos, NM 87544 |
| Event Date | Event Description |
| Monday, November 25, 2019 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, November 25, 2019 | ABANDONMENT - NO USE STATEMENT FILED |
| Wednesday, October 9, 2019 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Thursday, April 25, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, April 23, 2019 | EXTENSION 1 GRANTED |
| Tuesday, April 23, 2019 | EXTENSION 1 FILED |
| Tuesday, April 23, 2019 | TEAS EXTENSION RECEIVED |
| Tuesday, October 23, 2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, August 28, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 28, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 8, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, July 23, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, July 23, 2018 | EXAMINER'S AMENDMENT ENTERED |
| Monday, July 23, 2018 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, July 23, 2018 | EXAMINERS AMENDMENT E-MAILED |
| Monday, July 23, 2018 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, July 2, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, July 2, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, June 28, 2018 | ASSIGNED TO LIE |
| Friday, June 15, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, March 30, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, March 30, 2018 | NON-FINAL ACTION E-MAILED |
| Friday, March 30, 2018 | NON-FINAL ACTION WRITTEN |
| Wednesday, March 28, 2018 | ASSIGNED TO EXAMINER |
| Thursday, January 4, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Thursday, December 21, 2017 | NEW APPLICATION ENTERED IN TRAM |